- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04903899
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma (LuDO-N)
A Phase II Trial of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
The LuDO-N Trial is a multi-centre phase II clinical trial on 177Lu-DOTATATE treatment of recurrent or relapsed high-risk neuroblastoma in children. The LuDO-N Trial builds on the experience from the previous LuDO Trial and utilises an intensified dosing schedule to deliver 2 doses over a 2-week period, in order to achieve a maximal effect on the often rapidly progressing disease. This strategy requires a readiness for autologous stem cell transplantation in all patients, but is not anticipated to increase the risk of long-term sequelae, since the cumulative radiation dose remains unchanged. The primary aim of the study is to assess the response to 177Lu-DOTATATE treatment at 1 and 4 months after end of treatment. Secondary aims are to assess survival and treatment-related toxicity. Additional aim are to correlate tumour dosimetry with response, correlate SSTR-2 expression with 68Ga-DOTATATE uptake and to correlate the uptake with the treatment response.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Jakob Stenman, MD PhD
- Telefonnummer: 46 (0)51770000
- E-post: jakob.stenman@regionstockholm.se
Studer Kontakt Backup
- Navn: Kleopatra Georgantzi, MD
- Telefonnummer: 46 (0)51770000
- E-post: kleopatra.georgantzi@regionstockholm.se
Studiesteder
-
-
Copenhagen
-
Copenhagen, Copenhagen, Danmark, DK-2100
- Rekruttering
- Rigshospitalet
-
Ta kontakt med:
- Jesper S Brok, MD PhD
- E-post: jesper.sune.brok@regionh.dk
-
Hovedetterforsker:
- Jesper S Brok, MD PhD
-
-
-
-
Vilnius County
-
Vilnius, Vilnius County, Litauen, LT-08406
- Rekruttering
- Vilnius University Hospital
-
Ta kontakt med:
- Jelena Rascon, MD PhD
- E-post: jelena.rascon@gmail.com
-
Hovedetterforsker:
- Jelena Rascon, MD PhD
-
-
-
-
Utrecht
-
Utrecht, Utrecht, Nederland, NL-3584
- Rekruttering
- Princess Maxima Center for Pediatric Oncology
-
Ta kontakt med:
- Max M van Noesel, MD PhD
- E-post: M.M.vanNoesel@prinsesmaximacentrum.nl
-
Hovedetterforsker:
- Max M van Noesel, MD PhD
-
-
-
-
Oslo
-
Oslo, Oslo, Norge, NO-0372
- Rekruttering
- Oslo University Hospital, Rikshospitalet
-
Ta kontakt med:
- Kirsten Brunsvig Jarvis, MD
- E-post: kirjar@ous-hf.no
-
Hovedetterforsker:
- Kirsten Brunsvig Jarvis, MD
-
-
-
-
-
Barcelona, Spania
- Rekruttering
- Pediatric Cancer Center Barcelona, Sant Joan de Déu Barcelona Children's Hospital
-
Ta kontakt med:
- Maite Gorostegui Obanos, MD
- Telefonnummer: +34 93 280 40 00
- E-post: maite.gorostegui@sjd.es
-
Hovedetterforsker:
- Maite Gorostegui Obanos, MD
-
-
-
-
-
Glasgow, Storbritannia, G51 4TF
- Rekruttering
- GREATER GLASGOW HEALTH BOARD, Royal Hospital for Children
-
Ta kontakt med:
- Diana Mcintosh, Consultant Paediatric Oncologi
- E-post: Diana.Mcintosh2@nhs.scot
-
Hovedetterforsker:
- Diana Mcintosh, MD
-
London, Storbritannia, NW1 2PG
- Rekruttering
- University College London Hospitals NHS FOUNDATION TRUST
-
Ta kontakt med:
- Jenny Gains, Consultant in Clinical Oncolog
- Telefonnummer: +44-203 447 4437
- E-post: jenny.gains@nhs.net
-
Hovedetterforsker:
- Jenny Gains, MD
-
London, Storbritannia, SW3 6JJ
- Rekruttering
- The Royal Marsden NHS Foundation Trust of Fulham Road
-
Ta kontakt med:
- Sucheta Vaidya, Paediatric Oncologist
- E-post: Sucheta.Vaidya@rmh.nhs.uk
-
Hovedetterforsker:
- Sucheta Vaidya, MD
-
-
-
-
Stockholm County
-
Stockholm, Stockholm County, Sverige, SE-171 76
- Rekruttering
- Karolinska University Hospital
-
Hovedetterforsker:
- Kleopatra Georgantzi, MD
-
Ta kontakt med:
- Kleopatra Georgantzi, MD
- E-post: kleopatra.georgantzi@regionstockholm.se
-
Ta kontakt med:
- Jakob Stenman, MD PhD
- E-post: jakob.stenman@regionstockholm.se
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Pathology 1.1. Histologically confirmed diagnosis of neuroblastoma 1.2. Immunohistochemical staining for somatostatin receptors (SSTR) performed from primary tumor tissue when available
- Relapsed or primary refractory high-risk neuroblastoma: INSS stage 4 disease or INRGSS stage M disease
- Age >18 months at the time of enrolment into this study
- Life expectancy of greater than 3 months
- Performance Status 5.1. Karnofsky > 50% (for patients > 12 years of age) 5.2. Lansky > 50% (for patients ≤ 12 years of age)
- Prior treatment 6.1. Two-week washout from any prior treatment 6.2. Patients must have recovery of hematological toxicity following previous therapy 6.3. Adequate recovery from major surgery prior to receiving study treatment
- Diagnostic imaging 7.1. Uptake in the primary tumor or metastatic tumour deposits on 68Ga-DOTATATE PET/CT at least higher than the liver uptake and performed within two months prior to registration 7.2. 123I-mIBG scintigraphy to be performed within two months prior to registration 7.3. CT or MRI of the primary tumor and bulky metastatic sites within two months prior to registration
- Laboratory requirements to be performed within 7 days prior to commencing trial treatment 8.1. Hematology: 8.1.1. Hemoglobin, If Hb is <120 g/L then patient will receive a blood transfusion prior to commencing trial treatment 8.1.2. Absolute neutrophil count > 1.0 x 109/L 8.1.3. Absolute Platelets > 50 x 109/L 8.2. Biochemistry: 8.2.1. Bilirubin within 1.5 x ULN 8.2.2. ALT within 2.5 x ULN 8.2.3. AST within 2.5 x ULN 8.2.4. GGT within 5 x ULN 8.2.5. ALP within 5 x ULN 8.2.6. Glomerular filtration rate >50mL/min/1.73m2 assessed by a recognised method, such as inulin, 51Cr-EDTA, 99mTc-DTPA or iohexol clearance and performed within 2 months prior to registration 8.2.7. Urinary catecholamine metabolites measured within 2 months prior to registration
- Peripheral blood stem cells (PBSC) 9.1. A minimum of 2 x106 CD34+ cells/kg (optimally 6 x106 CD34+ cells/kg) must be available for each study subject prior to registration
- Written informed consent from patient and/or parent(s) or legal guardian(s) in accordance with national regulations, prior to registration or any trial-related screening procedures
Exclusion Criteria:
- Not fit enough to undergo proposed study treatment, as assessed by national PI, considering precautions defined in the latest version of the 177Lutetium-DOTATATE SmPC.
- Pregnant or lactating patient
- Concurrent treatment with any anti-tumor agents
- Prior treatment with other radiolabeled somatostatin analogues
- Hypersensitivity to any component of the investigational drug 177Lutetium-DOTATATE
- Treatment with long-acting somatostatin analogues within 30 days, or with short-acting somatostatin analogues within 24 hours prior the administration of 177Lutetium-DOTATATE
- Hydronephrosis in either kidney on baseline MRI or CT; patients can still be eligible for inclusion if urinary tract obstruction can be ruled out by renography
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: 177Lu-DOTATATE
A total of two doses of 177Lu-DOTATATE will be administered intravenously. The minimum time between treatments is 2 weeks. |
A total of two doses of 177Lu-DOTATATE will be administered intravenously. A weight-based activity of 400 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT/CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, to avoid renal toxicity. The aim is to deliver two doses of 177Lu-DOTATATE two weeks apart. The minimum time between treatments is 2 weeks. The maximum time between treatments is 4 weeks. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Response by the Revised International Neuroblastoma Response Criteria (INRC) at 1 month after the completion of therapy
Tidsramme: 1 months following end of treatment
|
Treatment response assessed in accordance with the Revised International Neuroblastoma Response Criteria (INRC) |
1 months following end of treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Response based on 68Ga-DOTATOC PET/CT imaging at 1 and 4 months after completion of therapy in measurable target lesions
Tidsramme: 1 and 4 months following end of treatment
|
Response based on 68Ga-DOTATOC PET/CT imaging after completion of therapy in measurable target lesions |
1 and 4 months following end of treatment
|
|
Response based on 123I-mIBG SPECT/CT imaging (when available) at 1 and 4 months after completion of therapy in measurable target lesions
Tidsramme: 1 and 4 months following end of treatment
|
Response based on 123I-mIBG SPECT/CT imaging (when available) after completion of therapy in measurable target lesions |
1 and 4 months following end of treatment
|
|
Response by the Revised INRC criteria at 4 months after the completion of therapy
Tidsramme: 4 months following end of treatment
|
Response by the Revised INRC criteria |
4 months following end of treatment
|
|
Progression-free survival
Tidsramme: Time from registration to progression or death, up to 5 years following end of treatment
|
Time to progress or death, whichever occurs first |
Time from registration to progression or death, up to 5 years following end of treatment
|
|
Overall survival - up to 5 years after End of Treatment
Tidsramme: Time from registration to the the date of death, up to 5 years following end of treatment
|
Overall survival |
Time from registration to the the date of death, up to 5 years following end of treatment
|
|
Hematological and renal toxicity according to CTCAE 5.0
Tidsramme: From first treatment dose until the date of first documented progression, assessed up to 60 months
|
Hematological and renal toxicity according to CTCAE 5.0 |
From first treatment dose until the date of first documented progression, assessed up to 60 months
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Dosimetry (absorbed dose in Gy) in measurable target lesions and risk organs
Tidsramme: At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)
|
Measured by SPECT/CT |
At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)
|
|
Semi-quantitative analysis of the expression of SSTR-2 on immunohistochemistry in the primary tumor histology
Tidsramme: Throughout the trial treatment phase (5 years)
|
Semi-quantitative analysis of the expression of SSTR-2 on immunohistochemistry in the primary tumor histology |
Throughout the trial treatment phase (5 years)
|
|
The uptake on 68Gallium-DOTATOC PET/CT by SUVmax (maximum standardized uptake value) in measurable target lesions
Tidsramme: At end of treatment, and 1 and 4 months after end of treatment.
|
Measured by SUVmax (maximum standardized uptake value) |
At end of treatment, and 1 and 4 months after end of treatment.
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Jakob Stenman, MD PhD, Karolinska University Hospital
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer
- Neoplasmer etter histologisk type
- Neoplasmer, kjertel og epitel
- Neoplasmer, Neuroepithelial
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Neuroektodermale svulster, primitive, perifere
- Neuroektodermale svulster, primitive
- Nevroblastom
- Lutetium Lu 177 Dotatat
Andre studie-ID-numre
- LuDO-N
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .